Abstract Group: 11.1. Lung Cancer

Keyword 1: Lung cancer / Oncology Keyword 2: Thoracic oncology Keyword 3: Palliative care

Title: Treatment of advanced non-small cell lung cancer with trofosfamide

Dr. Angelika 180 Reissig Angelika.Reissig@med.uni-jena.de MD and Dr. Mario 181 Walther Mario.Walther@mti.uni-jena.de . ¹ Pneumology & Allergology, Clinic for Internal Medicine I, University Hospital Jena, Friedrich-Schiller-University Jena, University Hospital Jena, Jena, Germany and ² Institute of Medical Statistics, Computer Sciences and Documentation, Friedrich-Schiller-University Jena, Germany, Institute of Medical Statistics, Jena, Germany .

Body: Introduction: The aim of this retrospective study was to examine the effect of oral trofosfamide in patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: Patients with histologically or cytologically proven NSCLC who had received at least two other therapies were enrolled. Primary clinical end point was progression-free survival (PFS); secondary end points included overall survival (OS), response rate and toxicity. Results: Twenty-three patients were enrolled, one of whom was excluded due to non-compliance. The patients had received a median of three prior therapies (range 2–4). Regarding all 22 patients, median PFS was 14 weeks (95% confidence interval (CI) 9.96–18.04). The median OS was 119 weeks (95% CI 85.67–152.33). The median duration of trofosfamide therapy was 10.5 weeks (interquartile range 6.5–17.3). Twenty patients (90.9%) had stable disease; two were not assessable. Trofosfamide therapy was stopped in four patients (18.2%) due to side effects. Conclusion: Trofosfamide is an orally applicable, well-tolerated and cost-effective drug that works in patients with advanced NSCLC who have undergone at least two lines of therapy. Trofosfamide seems to be a therapeutic option in NSCLC as a further therapy line. These preliminary data need to be confirmed in a larger trial.